Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8551681 | 0.86 | MAOB (0.43) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL992385 | 0.85 | CHRNA1 (0.49) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL8551682 | 0.84 | CHRNA1 (0.38) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL9046742 | 0.81 | TDP2 (0.48) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL8344971 | 0.79 | TSHR (0.35) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3327547 | 0.79 | CHRNA1 (0.47) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3786132 | 0.78 | SMN1; SMN2 (0.55) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL10627557 | 0.78 | CYP2A6 (0.41) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL5339706 | 0.77 | OPRD1 (0.49) | TSHRSMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL12823209 | 0.77 | TSHR (0.41) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| US-8536209-B2 | Aminotriazole derivatives as ALX agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| CN-101903353-B | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS LTD | 2013-04-10 | — | — | CN | disclosed |
| CN-102803237-A | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-28 | — | — | CN | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-1996036229-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0337176-B1 | Novel benzoic acid derivatives and process for preparing the same | SHUDO KOICHI (JP) | 1994-12-21 | — | — | EP | disclosed |
| EP-0411736-B1 | 11-Beta substituted 16-alpha, 17-alpha-methylene-estra-4,9-dien-3-one | SCHERING AG (DE) | 1994-05-04 | — | — | EP | disclosed |
| WO-1994008976-A1 | FUNGICIDAL AND MITICIDAL AMINOPYRIMIDINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5155249-A | Differentiating neoplastic cells, treating psoriasis, immune or inflammatory diseases | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5081271-A | Differentiation-inducing agent for neoplastic cells; therapeutic agent for psoriasis or immune and inflammatory diseases | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0411736-A1 | 11-Beta substituted 16-alpha, 17-alpha-methylene-estra-4,9-dien-3-one | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0337176-A2 | Novel benzoic acid derivatives and process for preparing the same | Shudo, Koichi, Prof. Dr. (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4004026-A | Dicarboxylic acids and derivatives in the treatment of pain and inflammation | CIBA-GEIGY CORPORATION (US) | 1977-01-18 | — | — | US | disclosed |
| US-3940434-A | ANTIINFLAMMATORY, ANALGESIC | CIBA-GEIGY CORPORATION (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | CHRNA1 259/4885CHRNG 560/4885CHRNB1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.